Enlivex Therapeutics Ltd's Comment on Sales, Marketing and Customers
The company serves customers, consumers, employees, and other stakeholders with interests in ESG issues, including climate change, energy and water use, plastic waste, and sustainability. It relies on third parties such as CROs, medical institutions, clinical investigators, contract laboratories, blood banks, collection service facilities, hospitals, health care providers, contract manufacturers, and collaboration partners to conduct clinical trials, collect starting materials, and manufacture product candidates for clinical trials and commercial use.
In a recent announcement, Enlivex Therapeutics Ltd. shared its plans to host an investor webinar aimed at discussing the promising interim data from its Phase I/II Allocetra trial, specifically for patients suffering from knee osteoarthritis (KOA). This announcement has garnered interest from investors and the broader pharmaceutical community due to the increasing prevalence of KOA and the potential for innovative therapeutic interventions.The Allocetra trial investigates the efficacy of Allocetra, a cell therapy designed to address the underlying mechanisms of inflammation and tissue regeneration in knee osteoarthritis. Early data suggest that Allocetra may improve patient outcomes by reducing inflammation ...
Recently, Enlivex Therapeutics Ltd. made a significant announcement regarding its ongoing clinical trial of Allocetra, aimed at patients suffering from moderate to severe knee osteoarthritis. This critical development follows a favorable interim data review by the independent Data and Safety Monitoring Board (DSMB), whose endorsement supports the transition from Phase I to Phase II of the trial. Facts from the Announcement: 1. Company Background: Enlivex Therapeutics Ltd. traded on Nasdaq as ENLV, is a clinical-stage biopharmaceutical company specializing in macrophage reprogramming immunotherapy. Their innovative therapies aim to modulate immune responses and improve outcomes in various inflammatory dis...
Enlivex Achieves Regulatory Milestone with Phase I Trial Authorization for Allocetra™ in Psoriatic Arthritis PatientsEnlivex Therapeutics Ltd, a clinical-stage immunotherapy company, has received regulatory authorization to initiate a Phase I clinical trial to evaluate its novel therapy, Allocetra™, in patients suffering from psoriatic arthritis. This represents a significant development in the pursuit of advanced treatment options for a chronic inflammatory condition that has, until now, seen limited therapeutic breakthroughs.Psoriatic arthritis affects up to 30% of individuals with psoriasis, manifesting as joint pain, swelling, and stiffness. Managing this ailment has proven challenging for medical p...
Nes-Ziona, Israel, April 22, 2024 - Enlivex Therapeutics Ltd., a revolutionary force in macrophage reprogramming immunotherapy, takes a significant step forward in the battle against knee osteoarthritis. The clinical-stage company today announced that the first two patients have been dosed in their multi-country, randomized, Phase I/II clinical trial. This trailblazing research evaluates the efficacy of Allocetra™ in up to 160 patients grappling with moderate to severe knee osteoarthritis.This randomized, controlled trial stands as a cornerstone in Enlivex s extensive and rigorous clinical development program, demonstrating the company s unwavering commitment to advancing science and improving patients li...
Enlivex Therapeutics Ltd., a clinical-stage macrophage reprogramming immunotherapy company, has announced that the Danish Medicines Agency (DKMA) has authorized the expansion of a multi-country clinical trial evaluating Allocetra™ in patients with knee osteoarthritis. This regulatory approval follows the initial authorization received from the Israeli Ministry of Health (IMOH) earlier this year.Phase I/II Trial Details:The randomized, controlled Phase I/II trial aims to evaluate the safety and efficacy of Allocetra™ in up to 160 patients with moderate to severe knee osteoarthritis. Allocetra™ is a novel immunotherapy designed to reprogram macrophages, a type of immune cell, to restore balance in the im...
Enlivex Therapeutics Ltd’s Comment on Sales, Marketing and Customers
The company serves customers, consumers, employees, and other stakeholders with interests in ESG issues, including climate change, energy and water use, plastic waste, and sustainability. It relies on third parties such as CROs, medical institutions, clinical investigators, contract laboratories, blood banks, collection service facilities, hospitals, health care providers, contract manufacturers, and collaboration partners to conduct clinical trials, collect starting materials, and manufacture product candidates for clinical trials and commercial use.
Sources:
Enlivex Therapeutics Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Enlivex Therapeutics Ltd’s corporate clients.
For your research, we’ve provided 9 tables on Enlivex Therapeutics Ltd corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
